RenovoRx Panther Study Progresses with First Clinical Procedure
RenovoRx has initiated its PanTheR post-marketing registry with the first registry-eligible patient procedure completed at the University of Vermont...
New Data: CNM-Au8 Improves Brain Energy Metabolism in MS
Topline data: In the combined Phase 2 REPAIR program, 12 weeks of CNM-Au8 increased the brain NAD+/NADH ratio by...
Sparrow’s Remarkable $95M To Advance Diabetes Treatment
Sparrow Pharmaceuticals raised $95 million in a Series B co-led by RA Capital Management and Forbion to advance clofutriben,...
Varmx Receives Key Phase 1 Waiver from Japan’s PMDA
Japan’s PMDA has waived the requirement for a domestic Phase 1 (ethnic bridging) study for VarmX’s VMX-C001, clearing the...
SAPU003 Trial: Full Everolimus Bioavailability for Cancer
Oral everolimus delivers roughly 10% bioavailability; Sapu003, an intravenous formulation, is designed to bypass absorption limits and deliver full...
DSMB Recommends Seastar Medical Continue Pivotal AKI Trial
Zero device-related adverse events were observed among the first 100 adult patients in SeaStar Medical’s NEUTRALIZE-AKI pivotal trial of...
New Drug Shows 86% Survival in Pancreatic Cancer Patients
Topline: In a single-arm Phase 2a cohort (N=34) of first-line pancreatic cancer, atebimetinib (IMM-1-104) plus modified gemcitabine/nab-paclitaxel delivered 86%...
Briumvi Data: Remarkable Halt to MS Disability Progression
Year 6 data from the ULTIMATE I & II open-label extensions showed an annualized relapse rate of 0.012 on...
Akari’s Novel ADC Payload Shows Potential in Preclinical Data
In preclinical models, Akari’s spliceosome-modulating ADC payload, PH1, suppressed AR-V7 expression in 22Rv1 metastatic castration-resistant prostate cancer cells and...
Sapu003 Trial Delivers New Hope for Breast Cancer Patients
Sapu Nano received Human Research Ethics Committee approval in Australia to initiate a Phase 1 study of Sapu003, an...